Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | AGER | Q15109 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28226024 | 0.78 | ALDH1A1 (0.39) | PKMTSHRGAAMEN1PABPC1 | |
| Methylamine SCHEMBL5149607 | 0.75 | APOBEC3A (0.47) | PKMTSHRGAAMEN1PABPC1 | |
| SCHEMBL67836 | 0.74 | APOBEC3A (0.50) | PKMTSHRGAAMEN1PABPC1 | |
| Methylamine SCHEMBL6091448 | 0.71 | PKM (0.57) | PKMTSHRGAAMEN1PABPC1 | |
| SCHEMBL11652492 | 0.71 | PKM (0.45) | PKMTSHRGAAMEN1PABPC1 | |
| SCHEMBL9363789 | 0.69 | ALDH1A1 (0.40) | TSHRGAAMEN1PABPC1KMT2A | |
| SCHEMBL27667967 | 0.69 | HCAR3 (0.45) | PKMTSHRGAAMEN1PABPC1 | |
| SCHEMBL19987779 | 0.69 | DPP4 (0.36) | ALDH1A1LMNAPTGS1PTGS2 | |
| SCHEMBL20366124 | 0.68 | PKM (0.58) | PKMTSHRGAAMEN1PABPC1 | |
| SCHEMBL70432 | 0.68 | TSHR (0.54) | PKMTSHRGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276300-A1 | REDUCTION OF MONOMERIC ISOCYANATES BY POROUS MATERIAL | BASF SE (DE) | 2025-09-04 | — | — | US | disclosed |
| EP-4291588-B1 | REDUCTION OF MONOMERIC ISOCYANATES BY POROUS MATERIAL | BASF SE (DE) | 2025-08-20 | — | — | EP | disclosed |
| EP-4291588-A1 | REDUCTION OF MONOMERIC ISOCYANATES BY POROUS MATERIAL | BASF SE (DE) | 2023-12-20 | — | — | EP | disclosed |
| CN-116829611-A | Reduction of monomeric isocyanates by porous materials | 巴斯夫欧洲公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3319966-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-01-29 | — | — | EP | disclosed |
| US-10287293-B2 | Bicyclic heterocyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287293-B2 | Bicyclic heterocyclic compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | PKM 439/4885TSHR 2792/4885GAA 230/4885 |
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE4D | PKM 439/4885TSHR 2792/4885GAA 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.